Eravacycline

Drug Profile

Eravacycline

Alternative Names: TP-434

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Tetraphase Pharmaceuticals
  • Class Acetamides; Antibacterials; Pyrrolidines; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Intra-abdominal infections; Urinary tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Intra-abdominal infections; Urinary tract infections
  • Phase I Respiratory tract infections

Most Recent Events

  • 17 Nov 2016 Tetraphase Pharmaceuticals announces intention to submit NDA to US FDA for complicated Intra-abdominal infections
  • 14 Oct 2016 Tetraphase Pharmaceuticals initiates dosing in a phase III IGNITE4 trial for Intra-abdominal infections in USA (9205155; 9206234)
  • 27 Sep 2016 Phase-III clinical trials in Intra-abdominal infections in Hungary (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top